Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-22
2011-03-22
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S274000
Reexamination Certificate
active
07910580
ABSTRACT:
Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.
REFERENCES:
patent: 504243 (1893-08-01), Philippot
patent: 1039140 (1912-09-01), Kampfe
patent: 1188697 (1916-06-01), Steinberg
patent: 1461366 (1923-07-01), Mulford et al.
patent: 1676146 (1928-07-01), Krafft
patent: 2021465 (1935-11-01), Ritscher
patent: 2609960 (1952-09-01), Irwin
patent: 2643024 (1953-06-01), Cronheim
patent: 2760672 (1956-08-01), Cronheim
patent: 3598105 (1971-08-01), Cristaldi
patent: 3809064 (1974-05-01), Ziegler
patent: 3961443 (1976-06-01), Insalaco
patent: 4000830 (1977-01-01), French
patent: 4350156 (1982-09-01), Malchesky et al.
patent: 4467784 (1984-08-01), Lee et al.
patent: 4482077 (1984-11-01), Henderson
patent: 4626536 (1986-12-01), Pfirrmann
patent: 4654345 (1987-03-01), Cavanak
patent: 4828140 (1989-05-01), Henderson
patent: 4960415 (1990-10-01), Reinmüller
patent: 5077281 (1991-12-01), Reinmüller
patent: 5167960 (1992-12-01), Ito et al.
patent: 5176651 (1993-01-01), Allgood et al.
patent: 5191900 (1993-03-01), Mishra
patent: 5208018 (1993-05-01), Gough
patent: 5210083 (1993-05-01), Pfirrman et al.
patent: 5262403 (1993-11-01), Nicolson et al.
patent: 5362754 (1994-11-01), Raad et al.
patent: 5416091 (1995-05-01), King
patent: 5441481 (1995-08-01), Mishra et al.
patent: 5554148 (1996-09-01), Aebischer et al.
patent: 5593665 (1997-01-01), Pfirrman et al.
patent: 5725553 (1998-03-01), Moenning
patent: 5730045 (1998-03-01), Delaquis et al.
patent: 5749859 (1998-05-01), Powell
patent: 5763421 (1998-06-01), Caretto et al.
patent: 5819748 (1998-10-01), Pfirrmann
patent: 5881905 (1999-03-01), Brady
patent: 5889183 (1999-03-01), Herdeis et al.
patent: 5957038 (1999-09-01), Shimazaki
patent: 6011030 (2000-01-01), Pfirrmann
patent: 6029843 (2000-02-01), Kroscher et al.
patent: 6030358 (2000-02-01), Odland
patent: 6035766 (2000-03-01), Schirmer
patent: 6080397 (2000-06-01), Pfirrmann
patent: 6093180 (2000-07-01), Elsberry
patent: 6105811 (2000-08-01), Alfred
patent: 6117868 (2000-09-01), Pfirrmann
patent: 6166007 (2000-12-01), Sodemann
patent: 6258797 (2001-07-01), Lehner
patent: 6303596 (2001-10-01), Morrissey et al.
patent: 6429224 (2002-08-01), Calabresi et al.
patent: 6479481 (2002-11-01), Stendel et al.
patent: 6521616 (2003-02-01), Calabresi et al.
patent: 6546849 (2003-04-01), Shimazaki
patent: 6617333 (2003-09-01), Rabindran et al.
patent: 6688487 (2004-02-01), Oakes et al.
patent: 6815441 (2004-11-01), Stendel et al.
patent: 6821968 (2004-11-01), Pfirrmann
patent: 6995164 (2006-02-01), Calabresi et al.
patent: 7151099 (2006-12-01), Redmond et al.
patent: 7345039 (2008-03-01), Redmond et al.
patent: 2001/0031870 (2001-10-01), Soll et al.
patent: 2002/0052366 (2002-05-01), Calabresi et al.
patent: 2002/0091123 (2002-07-01), Redmond et al.
patent: 2002/0098164 (2002-07-01), Redmond et al.
patent: 2002/0111328 (2002-08-01), Redmond et al.
patent: 2002/0111345 (2002-08-01), Calabresi et al.
patent: 2002/0131935 (2002-09-01), Fisher et al.
patent: 2003/0027818 (2003-02-01), Redmond et al.
patent: 2003/0092707 (2003-05-01), Redmond et al.
patent: 2003/0195198 (2003-10-01), Stendal et al.
patent: 2004/0087579 (2004-05-01), Redmond et al.
patent: 2302720 (2000-09-01), None
patent: 2393159 (2001-06-01), None
patent: 2393252 (2001-06-01), None
patent: 587040 (1977-04-01), None
patent: 3536560 (1986-04-01), None
patent: 19606897 (1997-08-01), None
patent: 0048558 (1982-03-01), None
patent: 0139535 (1985-05-01), None
patent: 0147021 (1985-07-01), None
patent: 0253662 (1988-01-01), None
patent: 1040841 (2000-10-01), None
patent: 1 066 830 (2001-01-01), None
patent: 1201247 (2002-05-01), None
patent: 1247524 (2002-10-01), None
patent: 2165752 (1986-04-01), None
patent: 60-105618 (1985-06-01), None
patent: 61-000017 (1986-01-01), None
patent: 63-72626 (1988-04-01), None
patent: 5-500973 (1993-02-01), None
patent: 5-505615 (1993-08-01), None
patent: 2000-300661 (2000-10-01), None
patent: 2000-516196 (2000-12-01), None
patent: 2001-10976 (2001-01-01), None
patent: 2002-326936 (2002-11-01), None
patent: WO 88/05301 (1988-07-01), None
patent: WO 91/13628 (1991-09-01), None
patent: WO 92/00743 (1992-01-01), None
patent: WO 95/18638 (1995-07-01), None
patent: WO 95/30423 (1995-11-01), None
patent: WO 97/25052 (1997-07-01), None
patent: WO 98/28027 (1998-07-01), None
patent: WO 98/39354 (1998-09-01), None
patent: WO 98/52572 (1998-11-01), None
patent: WO 99/06114 (1999-02-01), None
patent: WO 00/01391 (2000-01-01), None
patent: WO 01/39762 (2001-06-01), None
patent: WO 01/39763 (2001-06-01), None
patent: WO 02/07810 (2002-01-01), None
Bedrosian et al., “Taurolidine, an Analogue of the Amino Acid Taurine, Supresses Interleukin-1 and Tumor Necrosis Factor Synthesis in Human Peripheral Blood Mononuclear Cells”, Cytokine 3(6), 1991, pp. 568-575.
Braumann, et al., “The Influence of Intraoperative Intravenous and Intraperitoneal Application of Taurolidine with Heparin on Subcutaneous and Intraperitoneal Tumor Growth in Laparoscopic Surgery in a Rat Model”, Department of Surgery, Humboldt—Univerity of Berlin, Campus Chartie Mitte, Schumannstra. 20-21, 10098 Berlin, Germany, Apr. 14 and 15, 2000, 3 pages, (Abstract Book).
Bruckner, et al., “Taurolin:, Ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektionen”, Urban & Schwarzenberg Munchen Wien Baltimore 1985, (English Summary attached).
Campbell, et al., “The Role of Tumor Rejection Antigens in Host Antitumor Defense Mechanisms” Cancer, Jun. 1, 1995, vol. 75, No. 11,, pp. 2649-2655.
Carter, et al., “Chemotherapy of Cancer”, Scientific Library, Aug. 13, 1981, pp. 77-78.
Clarke et al., “KRN8602 (MX2-hydrochloride): An Active new Agent for the Treatment of Recurrent High-Grade Glioma”, J. Clin Oncol, Aug. 1999, 17(8): 2579-84, (Abstract only).
Da Costa, et al. “Laparotomy and Laparoscopy Differentially Accelerate Experimental Flank Tumor Growth”, British Journal of Surgery, 1998, 85, pp. 1439-1442.
Da Costa, et al., “The effect of Laparotomy and Laparoscopy on the Establishment of Spontaneous Tumor Metastases”, Surgery, vol. 124, No. 3, Sep. 1998, pp. 516-525.
Dimmock et al., “Mannich Bases of Phenolic Azobenzenes Possessing Cytotoxic Activity”, Eur. J. Med. Chem., vol. 32, 1997, pp. 583-594.
Erb, et al., “Structural Investigation of a New Organic Antiseptic: Taurolidine A Spectroscopic Study of Its Stability and Equilibria in Various Solvents”, Talanta. 1982, vol. 29., 953-958.
Erb, et al., “Structural Investigation of a New Organic Antiseptic: Taurolidine Analytical Study and Application to Identification and Quantitation in Biological Fluids” European Journal of Drug Metabolism and Pharmacokinetics, 1983, vol. 8, No. 2, pp. 163-173.
Fanning, et al., “Inhibition of Neutrophil Apoptosis after Elective Surgery”, Surgery, Sep. 1999, vol. 26, No. 3, pp. 527-534.
Finnegan, et al., “Cancer”, Jan. 1, 1998, vol. 82, No. 1., pp. 186-199.
Foye et al., “ACS Professional Reference Book” Cancer Chemotherapeutic Agents, American Cancer Society, 1995, pp. 50-55.
Gallagher, et al., “Hepatic Resection of Solitary Metastasis From Transitional Cell Carcinoma of the Bladder”, The Journal of Urology, Mar. 1998, vol. 159, p. 986.
Hansen et al., “Altretamine”, DICP, The Annals of Pharmacotherapy, 1991, vol. 25, 146-152.
Hood, et al., “Studies of the Thiadiazine, Taurolidine-I. Indentification of the Molecular Species Present in Aqueous Solutions by1H- and13C-NMR Spectroscopy”, Talanta, vol. 41, No. 1, pp. 107-113, 1994, pp. 107-113.
Jacobi et al., “Influence of Different Gases and Intraperitoneal Instillation of Antiadherent or Cytotoxic Agents on Peritoneal Tumor Cell Growth and Implantation with Laparoscopic Surgery in a Rat Model&#x
Pfirrmann Rolf W.
Redmond H. Paul
Anderson James D
Ed. Geistlich Soehne AG fuer Chemische Industrie
Rothwell Figg Ernst & Manbeck P.C.
LandOfFree
Enhancement of effectiveness of 5-Fluorouracil in treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhancement of effectiveness of 5-Fluorouracil in treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of effectiveness of 5-Fluorouracil in treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2725877